基于血液的生物标志物在慢性肝病肝纤维化分期中的准确性:支持AASLD实践指南的系统综述
本系统综述纳入286项研究、103,162例患者,评估血液标志物单独或联合诊断慢性肝病显著纤维化(F2-4)、进展性纤维化(F3-4)和肝硬化的效能。结果显示,在病毒性肝炎、HIV-HCV共感染和NAFLD中,血液标志物对诊断F2-4、F3-4和F4仅带来小到中等程度的验前概率改变,其他慢性肝病的比较或联合研究数据有限。
要点
- 在HBV、HCV、HIV-HCV/HBV共感染和NAFLD中,简单AST-to-platelet ratio index和FIB-4标志物研究最多,偏倚风险低至中等。
- HCV和HBV的F2-4、F3-4、F4阳性似然比分别为1.66-6.25和0.23-0.80、1.89-5.24和0.12-0.64、1.32-7.15和0.15-0.86。
- NAFLD的F2-4、F3-4、F4阳性似然比分别为2.65-3.37和0.37-0.39、2.25-6.76和0.07-0.87、3.90和0.15。
核心结论
- 血液标志物在病毒性肝炎、HIV-HCV共感染和NAFLD中诊断F2-4、F3-4和F4时,仅带来小到中等程度的验前概率改变,其他慢性肝病的比较或联合研究数据有限。
研究设计与样本
- 系统综述,检索Ovid MEDLINE(R)、EMBASE、Cochrane Database和Scopus至2022年4月,由两名独立审阅者筛选286项研究、共103,162例患者。
主要发现
- HCV和HBV的直接和间接标志物检测对F2-4、F3-4、F4的阳性似然比分别为1.66-6.25和0.23-0.80、1.89-5.24和0.12-0.64、1.32-7.15和0.15-0.86。
- NAFLD的F2-4、F3-4、F4阳性似然比分别为2.65-3.37和0.37-0.39、2.25-6.76和0.07-0.87、3.90和0.15。
- 总体比例优势比显示,FIB-4 <1.45优于AST-to-platelet ratio index <0.5(针对F2-4);FIB-4 >3.25也优于AST-to-platelet ratio index >1.5(针对F3-4和F4)。
- 联合检测的数据有限。
局限性
- 联合检测的数据有限。
- 其他慢性肝病的比较或联合研究数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Blood-based biomarkers have been proposed as an alternative to liver biopsy for noninvasive liver disease assessment in chronic liver disease. Our aims for this systematic review were to evaluate the diagnostic utility of selected blood-based tests either alone, or in combination, for identifying significant fibrosis (F2-4), advanced fibrosis (F3-4), and cirrhosis (F4), as compared to biopsy in chronic liver disease. APPROACH AND RESULTS: We included a comprehensive search of databases including Ovid MEDLINE(R), EMBASE, Cochrane Database, and Scopus through to April 2022. Two independent reviewers selected 286 studies with 103,162 patients. The most frequently identified studies included the simple aspartate aminotransferase-to-platelet ratio index and fibrosis (FIB)-4 markers (with low-to-moderate risk of bias) in HBV and HCV, HIV-HCV/HBV coinfection, and NAFLD. Positive (LR+) and negative (LR-) likelihood ratios across direct and indirect biomarker tests for HCV and HBV for F2-4, F3-4, or F4 were 1.66-6.25 and 0.23-0.80, 1.89-5.24 and 0.12-0.64, and 1.32-7.15 and 0.15-0.86, respectively; LR+ and LR- for NAFLD F2-4, F3-4, and F4 were 2.65-3.37 and 0.37-0.39, 2.25-6.76 and 0.07-0.87, and 3.90 and 0.15, respectively. Overall, the proportional odds ratio indicated FIB-4 <1.45 was better than aspartate aminotransferase-to-platelet ratio index <0.5 for F2-4. FIB-4 >3.25 was also better than aspartate aminotransferase-to-platelet ratio index >1.5 for F3-4 and F4. There was limited data for combined tests. CONCLUSIONS: Blood-based biomarkers are associated with small-to-moderate change in pretest probability for diagnosing F2-4, F3-4, and F4 in viral hepatitis, HIV-HCV coinfection, and NAFLD, with limited comparative or combination studies for other chronic liver diseases.
引用
- Patel K, Asrani SK, Fiel MI, et al. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology. 2024. PMID: 38489517. doi:10.1097/HEP.0000000000000842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。